Becaplermin

(BAN, USAN, rINN)
Synonyms: Becaplermina; Bécaplermine; Becaplerminum; Bekaplermiini; Bekaplermin; RWJ-60235. Recombinant human platelet-derived growth factor B.
Cyrillic synonym: Бекаплермин.

💊 Chemical information

CAS — 165101-51-9.
ATC — D03AX06.
ATC Vet — QD03AX06.

💊 Profile

Becaplermin is a recombinant human platelet-derived growth factor (rhPDGF-BB) that enhances the formation of granulation tissue and promotes wound healing. Becaplermin is applied topically as a 0.01% gel in the management of full thickness neuropathic diabetic skin ulcers. It is applied once daily, covered by a moist saline gauze dressing, for up to 20 weeks. If no meaningful healing process (decrease in ulcer size of about 30%) is evident after 10 weeks of therapy, treatment should be re-assessed. Becaplermin should not be applied to ulcers where neoplasms are present or to clinically infected ulcers. If the ulcer becomes infected during therapy, becaplermin should be stopped until the infection has cleared. US licensed product information warns that an increased rate of death from all cancers has been seen in patients treated with 3 or more tubes of becaplermin gel (tube size not specified). Becaplermin is used with a resorbable synthetic calcium phosphate matrix to promote bone and tissue growth in the treatment of periodontal disease. It is also under investigation in the treatment of osteonecrosis of the jaw, fractures, and osteoporosis, and in the repair of cartilage, ligament, and tendon injuries.
1. Wieman TJ, et al. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: a phase III randomized placebo-controlled double-blind study. Diabetes Care 1998; 21: 822–7
2. Smiell JM, et al. Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 1999; 7: 335–46
3. Guzman-Gardearzabal E, et al. Treatment of chronic ulcers in the lower extremities with topical becaplermin gel .01%: a multicenter open-label study. Adv Therapy 2000; 17: 184–9
4. Mandracchia VJ, et al. The use of becaplermin (rhPDGF-BB) gel for chronic nonhealing ulcers: a retrospective analysis. Clin Podiatr Med Surg 2001; 18: 189–209
5. Nagai MK, Embil JM. Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers. Expert Opin Biol Ther 2002; 2: 211–18
6. Nevins M, et al. Platelet-derived growth factor stimulates bone fill and rate of attachment level gain: results of a large multicenter randomized controlled trial. J Periodontol 2005; 76: 2205–15
7. McGuire MK, et al. rhPDGF-BB promotes healing of periodontal defects: 24-month clinical and radiographic observations. Int J Periodontics Restorative Dent 2006; 26: 223–31. Correction. ibid. 2007; 27: 88.

💊 Preparations

Proprietary Preparations

Austria: Regranex; Canad.: Regranex; Cz.: Regranex; Fr.: Regranex; Ger.: Regranex; Gr.: Regranex; Israel: Regranex; Mex.: Regranex; Neth.: Regranex; Port.: Regranex; Spain: Regranex; Switz.: Regranex; UK: Regranex; USA: Regranex. Multi-ingredient: USA: GEM 21S.
Published November 08, 2018.